In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
HealthDay on MSN2d
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for NowOn October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
Health on MSN2d
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss DrugsIn response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback